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Acute rejection of non-functional allograft in kidney transplant
recipients with hepatitis C treated with peginterferon-a2aTo the Editor:
Treatment of chronic hepatitis C in patients on hae-
modialysis awaiting renal transplantation (RTx) reduces
the risk of HCV-mediated allograft nephropathy and
improves graft survival [1]. Due to the toxicity of ribavi-
rin in haemodialysed patients, the antiviral treatment
has been traditionally limited to interferon a, with a
low rate of sustained virological response (SVR). Re-
cently, in a paper published by Rendina et al. [2], 34
out of 35 (97%) haemodialysed patients treated with a
tailored dose of peginterferon-a2a and ribavirin showed
SVR. The combined treatment had to be prematurely
terminated only in four individuals. In view of the 31
out of 35 patients (89%) ﬁnishing the treatment, the
authors concluded that peginterferon-a2a and ribavirin
in haemodialysed patients is a safe therapeutic option.
However, no information was given whether the 19
(54%) patients with failure of a previously transplanted
kidney had the failed graft retained in situ. In these pa-
tients, who represent a particular group in terms of ad-
verse eﬀects of interferon a-based therapy, the
conclusion drawn by Rendina et al. [2] may not entirely
apply.
We investigated 16 haemodialysed patients with
chronic hepatitis C awaiting RTx (Table 1). In all pa-
tients, therapy with peginterferon-a2a 180 lg once a
week was started. In four patients with a haemoglobin
concentration above 9.0 g/dL at week 4, ribavirin
200 mg twice a week was added. In eight patients, anti-
viral treatment was stopped at a median 24 (range 14–
32) weeks due to adverse events. Overall, eleven patients
showed SVR, two relapsed and three were non-respond-
ers. Consistent with the ﬁndings of Rendina et al. [2], the
SVR rate was higher in patients treated with peginterfer-
on-a2a and ribavirin (three out of four patients, 75%),
compared to eight out of 12 (66%) patients on peginter-
feron-a2a only, although the diﬀerence was insigniﬁcant.
Thirteen patients had previously undergone RTx. Six
patients, in whom the removal of non-functioning graft
was scheduled for the next RTx, had a retained graftin situ. Out of them, only two patients completed antivi-
ral therapy initiated 11 and 240 months after the graft
failure: one patient was a non-responder and one re-
lapsed. In two patients, who started the treatment at
17 and 48 months after the graft failure, therapy was
stopped at week 15 and 26 due to myocardial infarction
and dyspnoea, respectively. Unexpectedly, two patients,
who were put on antiviral treatment after four and eight
months of haemodialysis, developed acute rejection of
the retained non-functional graft.
The ﬁrst patient was a 25-year-old woman with end-
stage renal disease (ESRD) from the age of 18 due to
rapidly progressive glomerulonephritis, who received
her ﬁrst deceased donor renal transplant in October
2000, after being on haemodialysis for one year. Due
to graft failure caused by recurrent attacks of pyelone-
phritis, the patient has been haemodialysed since Febru-
ary 2006. During this time, HCV RNA in serum
appeared, and a liver biopsy proved chronic hepatitis
C with mild necroinﬂammatory activity and ﬁbrosis.
Upon therapy with peginterferon-a2a and ribavirin,
started in June 2006, SVR was achieved. However, eight
weeks after the onset of therapy, she experienced inter-
mittent chills and fever, with painful graft and arterial
hypertension ten weeks later. Antiviral treatment was
stopped at week 20 and the patient underwent graftecto-
my. Histology showed diﬀuse interstitial haemorrhage,
extensive interstitial inﬁltration by lymphocytes and
plasmocytes and transmural arteritis, compatible with
severe acute-on-chronic rejection.
The second patient, a 40-year-old male, with ESRD
due to focal segmental glomerulosclerosis (FSGS) since
the age of 17, had been haemodialysed for three months
before the ﬁrst cadaveric donor RTx was performed in
1983. Arterial stenosis and recurrence of FSGS resulted
in graft failure and second RTx in 2003. The second
graft failed in October 2005 due to HCV-associated glo-
merulonephritis and since then the patient has been on
haemodialysis. ‘‘Non-A, non-B” hepatitis was diag-
nosed in 1983 and a liver biopsy in 2001 showed chronic
Table 1
Demographic, laboratory and clinical characteristics of all patients at
baseline
N patients/HCV genotype 1b (%) 16/16 (100%)
Male (%) 12 (75%)
Age (median years, range) 47 (25–64)
Duration of haemodialysis (median years,
range)
14.5 (1–28)
HCV RNA (median IU/mL, IQRa) 18350 (910–469,000)
Outcome of antiviral therapy
(SVR/NR/Ra)
11 (68.8%)/3 (18.8%)/2
(12.5%)
Previous renal transplant (N, %) 13 (81.3%)
Retained graft in situ (N, %; median
months, range)
6 (37.5%); 14 (4–240)
a Abbreviations: IQR, interquartile range; SVR, sustained virologic
response; NR, non-responder; R, relapse.
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ity and ﬁbrosis. Antiviral therapy was begun in June
2006. Despite the withdrawal of ribavirin at week 4
due to anaemia, the patient attained SVR. However,
ten weeks after the onset of therapy, he experienced
chills, fever and a painful graft. Antiviral treatment
was stopped at week 14 and the patient underwent graf-
tectomy. Compatible with the acute-on-chronic allograft
rejection, the histology showed almost complete haem-
orrhagic necrosis of the graft.
In line with previous case records [3,4] and a recent
cohort study [5], and contrary to the study of Rendina
et al. [2], we conclude that even haemodialysed patients
with non-functional renal allograft retained in situ may
experience acute allograft rejection following peginter-
feron-a2a treatment of hepatitis C. Before the start of
antiviral therapy, these patients may need to be advised
of this eventuality and should be aware of the possible
need for graftectomy. In patients who present with graft
failure less than one year prior to treatment withpeginterferon-a and who seem to be most prone to acute
rejection, it may seem reasonable to endorse preemptive
graftectomy.
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with peginterferon alpha-2a: Reply2To the Editor:
We have read very carefully the Letter to the Editor
by Dr. Sperl and collegues and the answers to the ques-
tions they raised are provided below:
1. In our series, of the 19 haemodialysed patients, who had
previously been transplanted, 14 had retained the graft
in situ. Five patients, before treatment, had already been
submitted to graftectomy on account of symptoms such
as, for example, acute rejection which occurred after a
mean time of 3–7 months after graft failure. As far asconcerns immunosuppressive treatment, the policy in
our centre is to stop Calcineurin inhibitors and to taper
steroids within 3 months of graft failure. Our patients
received anti-viral treatment only after a mean period
of 12–36 months after graft failure.
. In the series described by Dr. Sperl, interferon treat-
ment was started very early after graft loss (i.e., 4 and
8 months) and no information is provided regarding
either immunosuppressive treatment or the immuno-
logical background of the two patients. We chose to
start treatment after a period of clinical and immuno-
